| [1] | 张路, 李剑.Castleman病发病机制研究进展[J].中国医学科学院学报, 2016, 38:118-121. |
| [2] | Yuan XG, Hu W, Chen FF, et al.Renal complications of Castleman's disease:report of two cases and analysis of 75 cases[J].Clin Exp Nephrol, 2011, 15:921-926. |
| [3] | El KK, Vuiblet V, Dion D, et al.Renal involvement in Castleman disease[J].Nephrol Dial Transplant, 2011, 26:599-609. |
| [4] | Xu D, Lv J, Dong Y, et al.Renal involvement in a large cohort of Chinese patients with Castleman disease[J].Nephrol Dial Transplant, 2012, 27 Suppl 3:i119-i125. |
| [5] | 王素霞, 邹古明, 章友康, 等.Castleman病肾损害的临床病理分析[J].中华肾脏病杂志, 2009, 25:585-590. |
| [6] | Zhang L, Li Z, Cao X, et al.Clinical spectrum and survival analysis of 145 cases of HIV-negative Castleman's disease:renal function is an important prognostic factor[J].Sci Rep, 2016, 6:23831. |
| [7] | Kanda J, Kawabata H, Yamaji Y, et al.Reversible cardiomyopathy associated with Multicentric Castleman disease:successful treatment with tocilizumab, an anti-interleukin 6 receptor antibody[J].Int J Hematol, 2007, 85:207-211. |
| [8] | Man L, Goudar RK.Reversal of cardiomyopathy with tocilizumab in a case of HIV-negative Castleman's disease[J].Eur J Haematol, 2013, 91:273-276. |
| [9] | Yasuda S, Tanaka K, Ichikawa A, et al.Aggressive TAFRO syndrome with reversible cardiomyopathy successfully treated with combination chemotherapy[J].Int J Hematol, 2016, 104:512-518. |
| [10] | Yamamoto S, Nakatani S, Kijima K, et al.[Multicentric Castleman's disease with reversible left ventricular diffuse hypokinesis][J].Nihon Naika Gakkai Zasshi, 2001, 90:123-126. |
| [11] | Shirakawa K, Egashira T, Ieda M, et al.Multidisciplinary approach to the treatment of cardiac AA amyloidosis and aortic stenosis due to Castleman's disease:a hybrid therapy with tocilizumab and aortic valve replacement[J].Int J Cardiol, 2014, 173:e9-e11. |
| [12] | 张路, 李剑.多中心型Castleman病的治疗进展[J].国际药学研究杂志, 2017, 44:162-166. |
Figures(3)
Supported by:
Beijing Renhe Information Technology Co. Ltd
Submit
Review
Office
Email Alert
RSS
DownLoad:
